Drugs / Atenativ
Atenativ
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04745442 | Apr → Dec 2020 | COVID-19, acute respiratory distress syndrome, severe acute respiratory syndrome | Maimónides Biomedical Research Institute of Córdoba | Completed | No outcome recorded |
| Phase 2 | NCT02037555 | Jun 2014 → Jan 2018 | — | Grifols Therapeutics LLC | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03208270 | Jul 2017 → May 2019 | — | Policlinico Hospital | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06096116 | Aug 2024 → Mar 2028 expected | acquired coagulation factor deficiency | Octapharma | Recruiting | No outcome recorded |
| Phase 3 | NCT04918173 | Jul 2022 → Dec 2026 expected | hereditary antithrombin deficiency | Octapharma | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02278575 | Jan 2016 → May 2017 | blood coagulation disease | Vastra Gotaland Region | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06145373 Background | Mar 2024 → May 2028 expected | hemophilia A | Sanofi | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atenativ | “Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating...” NCT06096116 ↗ |
| Known as | Antithrombin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03208270 ↗ |
| Known as | Antithrombin concentrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06145373 ↗ |
| Known as | AT-III (Human) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02037555 ↗ |
| Action | Restore | “evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring and maintaining heparin responsiveness” NCT06096116 ↗ |
| Modality | Protein / enzyme biologic | “AT-III (Human) is an antithrombin concentrate prepared from pooled human plasma.” NCT02037555 ↗ |
| Route | Intravenous | “AT-III (Human) is provided as a freeze-dried preparation for intravenous use.” NCT02037555 ↗ |